featured
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial
JAMA Oncol 2020 Apr 30;[EPub Ahead of Print], PJ Bröckelmann, H Goergen, U Keller, J Meissner, R Ordemann, TV Halbsguth, S Sasse, M Sökler, A Kerkhoff, S Mathas, A Hüttmann, M Bormann, A Zimmermann, J Mettler, M Fuchs, B von Tresckow, C Baues, A Rosenwald, W Klapper, C Kobe, P Borchmann, A EngertFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.